The Bill & Melinda Gates Foundation is known for spending billions to fight infectious diseases in developing countries, so a new investment in a French biotech company feels somewhat unusual.
Smart Immune will receive $5 million from the foundation, according to the Financial Times. The company has developed a thymus-empowered T-cell therapy platform, called ProTcell, “to fully and rapidly re-arm the immune system.”
